ANXA2 and gastric carcinoma: Emoto et al. demonstrated that thirty-three percent of 153 primary gastric carcinoma patients are immunopositive for ANXA2; however, overexpression of ANXA2 is correlated with differentiation, lymph node metastasis, and venous invasion [61].